1. Home
  2. DVN vs BIIB Comparison

DVN vs BIIB Comparison

Compare DVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Devon Energy Corporation

DVN

Devon Energy Corporation

HOLD

Current Price

$36.15

Market Cap

22.2B

Sector

Energy

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$170.45

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVN
BIIB
Founded
1971
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
DVN
BIIB
Price
$36.15
$170.45
Analyst Decision
Buy
Buy
Analyst Count
21
22
Target Price
$43.53
$177.40
AVG Volume (30 Days)
8.2M
2.0M
Earning Date
11-05-2025
10-30-2025
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
4.24
10.97
Revenue
$16,554,000,000.00
$10,065,900,000.00
Revenue This Year
$13.09
$3.61
Revenue Next Year
N/A
N/A
P/E Ratio
$8.71
$15.68
Revenue Growth
13.94
4.77
52 Week Low
$25.89
$110.04
52 Week High
$38.88
$185.17

Technical Indicators

Market Signals
Indicator
DVN
BIIB
Relative Strength Index (RSI) 49.29 47.81
Support Level $34.91 $169.52
Resistance Level $37.04 $175.94
Average True Range (ATR) 0.93 5.18
MACD -0.28 -1.99
Stochastic Oscillator 33.58 10.97

Price Performance

Historical Comparison
DVN
BIIB

About DVN Devon Energy Corporation

Devon Energy is an oil and gas producer with acreage in several top US shale plays. While roughly two thirds of its production comes from the Permian Basin, it also holds a meaningful presence in the Anadarko, Eagle Ford, and Bakken basins. At the end of 2024, Devon reported net proved reserves of 2.2 billion barrels of oil equivalent. Net production averaged roughly 848,000 barrels of oil equivalent per day in 2024 at a ratio of 73% oil and natural gas liquids and 27% natural gas.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: